SPRAVATO - Johnson & Johnson
2 days ago · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is …
FDA approves Johnson & Johnson’s nasal spray for depression …
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults with a major depressive disorder that is difficult to treat, as sales of the drug grow. …
FDA approves standalone use of J&J’s ketamine-derived depression ...
2 days ago · The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe …
FDA approves first-of-its-kind nasal spray for severe depression
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), …
FDA approves Johnson & Johnson’s ketamine-derived nasal …
17 hours ago · FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment Beth Greenfield Updated Thu, January 23, 2025 at 3:48 PM UTC
FDA approves Spravato, first monotherapy nasal spray to treat depression
3 days ago · The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat …
FDA Approves Johnson & Johnson's Spravato as Standalone …
2 days ago · The Food and Drug Administration has approved Johnson & Johnson's nasal spray Spravato (esketamine) as a standalone treatment for adults with treatment-resistant …
Johnson & Johnson pivotal study of seltorexant shows …
Titusville, New Jersey (May 29, 2024) – Johnson & Johnson announced today positive topline results from the pivotal Phase 3 MDD3001 clinical trial evaluating the efficacy and safety of …
J&J's drug eases depression and insomnia symptoms in late-stage …
May 29, 2024 · Johnson & Johnson's experimental drug helped reduce symptoms of depression as well as insomnia in patients with major depressive disorder (MDD) in a late-stage trial, the …
Johnson & Johnson ketamine-derived nasal spray gets FDA …
1 day ago · Johnson & Johnson beat analyst expectations for revenue by $70 million, but highlighted possible negative impacts in its outlook from an ongoing talc lawsuit and slower …